Takeda Alliance Boosts Liver Disease Venture Ambys’s $140m Launch

Takeda is investing in newly launched serious liver disease company Ambys Medicines to support the advancement of the US venture’s platform and pipeline, in line with its core strategic therapeutic priorities.

Liver cancer, CT scan upper abdomen.
NEW VENTURE AMBYS EYES NOVEL APPROACHES TO LIVER DISEASE • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. is providing substantial launch support to a new US venture focusing on novel regenerative approaches to serious liver diseases, in a move the company says aligns with its strategic focus areas. 

The Japanese firm has committed total funding of $100m to Ambys Medicines, including participation in the start-up’s $60m Series A...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category